Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eltoprazine - Elto Pharma

Drug Profile

Eltoprazine - Elto Pharma

Alternative Names: DU-28853; Eltoprazine

Latest Information Update: 04 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Solvay
  • Developer Elto Pharma; PsychoGenics; Solvay
  • Class Antidepressants; Antipsychotics; Piperazines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase II Aggression; Drug-induced dyskinesia
  • No development reported Cognition disorders
  • Discontinued Psychotic disorders

Most Recent Events

  • 24 Oct 2019 Amarantus enter into a binding term sheet to license Eltoprazine to Emerald Organic Growth worldwide
  • 20 Jul 2018 Elto Pharma expects to initiate the phase IIb trial for Parkinson's disease levadopa-induced dyskinesia in the first half of 2019
  • 01 May 2018 The Canadian Intellectual Property Office issues a Notice of Allowance for a patent application in non-Attention-deficit hyperactivity disorder neurological and mental disorders, including Parkinson's disease and Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top